Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Inclusion Criteria:

- Type 2 diabetes with Hemoglobin A1c equal to or less than 9.5% (equal to or less than
81 mmol/mol)

- Anti-hyperglycemic drug naive or treated with up to 2 oral hyperglycemic drugs with or
without a glucagon-like peptide-1analog or basal insulin, or basal insulin alone

- On stable antihyperglycemic regimen for at least 3 months

- Age equal to or greater than 50 years with established clinical vascular disease, or
age equal to or greater than 55 years and subclinical vascular disease or age equal to
or greater than 60 years and at least 2 or more cardiovascular risk factors

Exclusion Criteria:

- Uncontrolled diabetes requiring immediate therapy

- History of severe hypoglycemia in past year

- Acute coronary or cerebrovascular event within past 2 months

- Planned or anticipated revascularization procedure

- History of pancreatitis, hepatic insufficiency , chronic renal failure or of C-cell
thyroid disorder

- Pregnancy or planned pregnancy during the trial period

- Completed or withdrawn from any study investigating dulaglutide